Abstract
Delirium is an acute change in cognition, common in hospitalised older adults, and associated with high healthcare and human cost. In this work we shed light into the currently poorly understood genetic and proteomic background of delirium. We conducted the largest to date multi-ancestry analysis of genetic variants associated with delirium (1,059,130 individuals, 11,931 cases), yielding the Apolipoprotein E (APOE) gene as a strong risk factor with possible population and age-varying effects. A multi-trait analysis of delirium with Alzheimer disease identified 5 delirium genetic risk loci. Investigation of plasma proteins associated with up to 16-years incident delirium (32,652 individuals, 541 cases) revealed known and novel protein biomarkers, implicating brain vulnerability, inflammation and immune response processes. Integrating proteins and APOE genetic risk with demographics significantly improved incident delirium prediction compared to demographics alone. Our results pave the way to better understanding delirium’s aetiology and guiding further research on clinically relevant biomarkers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the Legal & General Group (research grant to establish the independent Advanced Care Research Centre at University of Edinburgh). The funder had no role in conduct of the study, interpretation or the decision to submit for publication. The views expressed are those of the authors and not necessarily those of Legal & General.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank project was approved by the National Research Ethics Service Committee North West-Haydock (REC reference: 11/NW/0382). Participants provided written informed consent to participate in the UK Biobank. An electronic signed consent was obtained from the participants. This research was conducted using the UK Biobank Resource under project 788.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Details for accessing individual-level data can be found here:
for UK Biobank https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access
for All of Us Research Programme https://www.researchallofus.org/register
Details on obtaining delirium GWAS summary statistics used in this work can be found here:
for FinnGen R10 release https://www.finngen.fi/en/access_results
for MGI freeze 3 https://precisionhealth.umich.edu/our-research/michigangenomics
Summary statistics generated in this work will be made publicly available upon publication.
